News
ADCT
3.980
-0.75%
-0.030
Weekly Report: what happened at ADCT last week (0202-0206)?
Weekly Report · 11h ago
ADC Therapeutics SA's (NYSE:ADCT) Price Is Right But Growth Is Lacking
Simply Wall St · 4d ago
ADC Therapeutics participates in a conference call with Cantor
TipRanks · 6d ago
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
PR Newswire · 6d ago
Weekly Report: what happened at ADCT last week (0126-0130)?
Weekly Report · 02/02 10:01
Weekly Report: what happened at ADCT last week (0119-0123)?
Weekly Report · 01/26 10:01
Weekly Report: what happened at ADCT last week (0112-0116)?
Weekly Report · 01/19 10:05
Analysts’ Top Healthcare Picks: TriSalus Life Sciences (TLSI), Outset Medical (OM)
TipRanks · 01/13 02:10
ADC Therapeutics outlines ZYNLONTA-focused growth and financing strategy
TipRanks · 01/12 14:04
Weekly Report: what happened at ADCT last week (0105-0109)?
Weekly Report · 01/12 10:05
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 01/09 12:02
ADC Therapeutics Announces Preliminary 2025 Financial Results and Outlook
TipRanks · 01/08 22:28
ADC Therapeutics posts preliminary 2025 revenue of about $73M
Seeking Alpha · 01/08 21:25
ADC Therapeutics sees FY25 net product revenue $73M
TipRanks · 01/08 21:17
ADC Therapeutics Reports Q4, 2025 Preliminary ZYNLONTA Net Product Revenue Of ~$22M, ~$73M, Respectively
Benzinga · 01/08 21:16
ADC Therapeutics sees Q4 net product revenue $22M
TipRanks · 01/08 21:10
ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates
PR Newswire · 01/08 21:05
ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
PR Newswire · 01/08 12:15
More
Webull provides a variety of real-time ADCT stock news. You can receive the latest news about Adc Therapeutics Sa through multiple platforms. This information may help you make smarter investment decisions.
About ADCT
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.